Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT-Reference-Cited by-同舟云学术

Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT

Published:2022-09-16 Issue:12 Volume:57 Page:1788-1796
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Nagler Arnon^ORCID,Ngoya Maud^ORCID,Galimard Jacques-Emmanuel^ORCID,Labopin Myriam^ORCID,Kröger Nicolaus^ORCID,Socié Gerard^ORCID,Gedde-Dahl Tobias,Potter Victoria,Schroeder Thomas,Platzbecker Uwe,Ganser Arnold,Blaise Didier^ORCID,Salmenniemi Urpu,Maertens Johan,Craddock Charles^ORCID,Labussière-Wallet Hélène,Yakoub-Agha Ibrahim^ORCID,Savani Bipin^ORCID,Mohty Mohamad^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01825-0.pdf

Reference37 articles.

1. Granfeldt Ostgard LS, Medeiros BC, Sengelov H, Norgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute MSecondary AML is generally associated with poor clinical outcomes compared to de novo AMLyeloid Leukemia: a National Population-Based Cohort Study. J Clin Oncol. 2015;33:3641–9.

2. Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90:208–14.

3. Della Porta MG. Prognosis of secondary acute myeloid leukemia. Leuk Res. 2013;37:857–8.

4. Park SH, Chi H-S, Cho Y-U, Jang S, Park C-J. Evaluation of prognostic factors in patients with therapy-related acute myeloid leukemia. Blood Res. 2013;48:185.

5. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19:1405–13.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT;Blood Advances;2024-08-13

2. Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry;Bone Marrow Transplantation;2024-01-09

3. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT;Bone Marrow Transplantation;2023-09-02

4. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT;Journal of Hematology & Oncology;2023-05-29

5. Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Therapy-Related Acute Myeloid Leukemia: a Retrospective Multicentre Study on behalf of the SFGM-TC;2023-03-01